Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Anergen in-licenses MHC II-peptide complex with potential applications in MS

Sep. 21, 1998

Search for 5-HT2C ligands at Organon leads to the full agonist Org-38457

Sep. 18, 1998

Yale University studies suggest potential new therapeutic target for schizophrenia

Sep. 18, 1998

Neurogen epilepsy drug candidate undergoes further preclinical trials

Sep. 17, 1998

IND filed for new insomnia drug candidate from Neurogen and Pfizer

Sep. 17, 1998

GW-273227, a sodium channel blocker for the treatment of pain

Sep. 17, 1998

Glaxo Wellcome studies lamotrigine analogues in the search for new anticonvulsants

Sep. 17, 1998

Astra Arcus develops first full, selective alpha7 nAChR agonist

Sep. 17, 1998

Selective 5-HT2C antagonist selected for development at Organon

Sep. 17, 1998

European marketing application for Myotrophin withdrawn

Sep. 16, 1998

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...